Locally Advanced or Metastatic Urothelial Carcinoma (UC)

Also known as: Locally Advanced or Metastatic Urothelial Carcinoma

DrugDrug NameDrug Description
DB13007Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
DB12147ErdafitinibA fibroblast growth factor receptor tyrosine kinase inhibitor used to treat locally advanced or metastatic urothelial carcinoma.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DB12893Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
DrugDrug NamePhaseStatusCount
DB11595Atezolizumab2Active Not Recruiting1
DB00515Cisplatin2Active Not Recruiting1
DB00441Gemcitabine2Active Not Recruiting1
DB12893Sacituzumab govitecan2Recruiting1
DB00958Carboplatin3Not Yet Recruiting1
DB00515Cisplatin3Not Yet Recruiting1
DB00441Gemcitabine3Not Yet Recruiting1
DB15043Toripalimab3Not Yet Recruiting1
DB13007Enfortumab vedotinNot AvailableApproved for Marketing1